Summary："Breakthrough Study Validates GraftAssure's Superiority Over Competing NGS Assay in Clinical Chemist

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"Breakthrough Study Validates GraftAssure's Superiority Over Competing NGS Assay in Clinical Chemistry"

NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx"), a leading innovator in molecular diagnostics, today announced the online publication of a landmark study in Clinical Chemistry, the prestigious, peer-reviewed journal of the American Association for Clinical Chemistry. The study conclusively demonstrates the superiority of iMDx's proprietary GraftAssure test over a competing Next-Generation Sequencing (NGS) assay in detecting graft injury and predicting allograft loss in kidney transplant patients.

The key findings of the study reveal that GraftAssure exhibited significantly higher sensitivity and specificity compared to the competing NGS assay, underscoring its potential to revolutionize post-transplant monitoring. By leveraging a unique, patented algorithm that integrates multiple biomarkers, GraftAssure provides clinicians with a more accurate and actionable assessment of graft health. The study's results are poised to reshape the clinical management of kidney transplant patients, enabling healthcare providers to identify potential complications earlier and intervene more effectively.

Industry analysts are hailing the study's publication as a significant validation of GraftAssure's clinical utility and a major milestone for iMDx. As the demand for precision diagnostics continues to escalate, the study's findings are expected to drive increased adoption of GraftAssure among transplant centers and clinicians. Moreover, the study's results may prompt a reevaluation of current clinical guidelines and standards of care for post-transplant monitoring, potentially expanding the market opportunity for GraftAssure.

Looking ahead, iMDx is poised to capitalize on the momentum generated by the study's publication. The company plans to accelerate the commercialization of GraftAssure, with a focus on expanding its presence in key markets and fostering strategic partnerships with leading healthcare organizations. As the company continues to execute on its growth strategy, investors and industry stakeholders will be watching closely for further developments.

In conclusion, the publication of this groundbreaking study in Clinical Chemistry represents a major triumph for iMDx and a significant advancement in the field of molecular diagnostics. With GraftAssure's proven superiority over competing NGS assays, iMDx is well-positioned to drive innovation and improve patient outcomes in the rapidly evolving landscape of transplant medicine.